Tat Ming Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tat Ming Ng has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- David Chien Lye
National Centre for Infectious Diseases, Singapore, Singapore
14 shared publications Shi Thong Heng
Tan Tock Seng Hospital, Singapore, Singapore
7 shared publicationsSock Hoon Tan
Department of Pharmacy, Tan Tock Seng Hospital, Singapore, Singapore
7 shared publicationsTau Hong Lee
Tan Tock Seng Hospital, Singapore, Singapore
6 shared publicationsChristine B. Teng
Department of Pharmacy, Tan Tock Seng Hospital, Singapore, Singapore
5 shared publicationsMin Yi Yap
Department of Pharmacy, Tan Tock Seng Hospital, Singapore, Singapore
5 shared publications
Latest Publications
- 14 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis
While nirmatrelvir‐ritonavir effectively prevents severe COVID‐19, its ritonavir component causes significant drug–drug interactions (DDIs). Current guidelines suggest mitigating this interaction by halving the amlodipine dose or moving to every‐other‐day (EOD) dosing, then resuming the standard regimen 3–5 days post‐antiviral treatment. We applied physiologically based pharmacokinetic/pharmacodynamic (PBPK‐PD) modeling to evaluate the effects of these recommendations on systolic blood pressure (SBP) control. SARS‐CoV‐2 inpatients who received nirmatrelvir‐ritonavir (October–December 2022) and were exposed to potential DDIs were identified. An amlodipine PBPK‐PD model incorporating the diurnal variation of SBP was developed. The model was validated using amlodipine PK studies, including in DDI scenarios, while the PD model was validated against SBP data collected during amlodipine treatment. Simulations were performed in representative virtual populations, comprising various amlodipine doses and regimens, during and after nirmatrelvir‐ritonavir therapy. 362/1729 (20.9%) drugs from 166/217 (76.5%) patients were identified to have potential DDIs implicating nirmatrelvir‐ritonavir. Amlodipine was a common interacting drug (64/362, 17.7%) and often prescribed without dose adjustment (63%). Our simulations supported that continuing amlodipine during therapy may lead to SBP ≤100 mmHg at daily doses of ≥5 mg, while discontinuation may lead to SBP >130–150 mmHg. Halving the amlodipine dose during nirmatrelvir‐ritonavir treatment could provide more stable SBP control than EOD dosing. Resuming usual doses 3 days after nirmatrelvir‐ritonavir could be more important in those receiving 7.5 and 10 mg of amlodipine. DDIs between nirmatrelvir‐ritonavir and amlodipine were common. Our simulations evaluated current dose adjustment recommendations for amlodipine with mechanistic quantitative reasoning.
- 14 November 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis
While nirmatrelvir‐ritonavir effectively prevents severe COVID‐19, its ritonavir component causes significant drug–drug interactions (DDIs). Current guidelines suggest mitigating this interaction by halving the amlodipine dose or moving to every‐other‐day (EOD) dosing, then resuming the standard regimen 3–5 days post‐antiviral treatment. We applied physiologically based pharmacokinetic/pharmacodynamic (PBPK‐PD) modeling to evaluate the effects of these recommendations on systolic blood pressure (SBP) control. SARS‐CoV‐2 inpatients who received nirmatrelvir‐ritonavir (October–December 2022) and were exposed to potential DDIs were identified. An amlodipine PBPK‐PD model incorporating the diurnal variation of SBP was developed. The model was validated using amlodipine PK studies, including in DDI scenarios, while the PD model was validated against SBP data collected during amlodipine treatment. Simulations were performed in representative virtual populations, comprising various amlodipine doses and regimens, during and after nirmatrelvir‐ritonavir therapy. 362/1729 (20.9%) drugs from 166/217 (76.5%) patients were identified to have potential DDIs implicating nirmatrelvir‐ritonavir. Amlodipine was a common interacting drug (64/362, 17.7%) and often prescribed without dose adjustment (63%). Our simulations supported that continuing amlodipine during therapy may lead to SBP ≤100 mmHg at daily doses of ≥5 mg, while discontinuation may lead to SBP >130–150 mmHg. Halving the amlodipine dose during nirmatrelvir‐ritonavir treatment could provide more stable SBP control than EOD dosing. Resuming usual doses 3 days after nirmatrelvir‐ritonavir could be more important in those receiving 7.5 and 10 mg of amlodipine. DDIs between nirmatrelvir‐ritonavir and amlodipine were common. Our simulations evaluated current dose adjustment recommendations for amlodipine with mechanistic quantitative reasoning.
- Open Access
- 18 July 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (7) , 722
Should Cefoxitin Non-Susceptibility in Ceftriaxone-Susceptible E. coli and K. pneumoniae Prompt Concerns Regarding Plasmid-Mediated AmpC Resistance? A Genomic Characterization and Summary of Treatment Challenges in Singapore
Objectives: Plasmid-mediated AmpC beta-lactamases represent a growing clinical concern in Enterobacterales, with challenges in diagnostic approaches, limited data on clinical outcomes, and our incomplete understanding of their regulatory mechanisms warranting the need for further investigation. Methods: This retrospective study examined the genomic and clinical characteristics of cefoxitin-non-susceptible, ceftriaxone-susceptible Escherichia coli and Klebsiella pneumoniae bloodstream isolates collected from a tertiary hospital in Singapore. Whole-genome sequencing was performed to detect ampC genes, subtypes, and associated regulatory elements. Results: Among 108 cefoxitin-non-susceptible isolates, only 15 (13.9%) harboured plasmid-mediated ampC, suggesting that cefoxitin non-susceptibility alone in ceftriaxone susceptible isolates was not predictive of ampC carriage. All plasmid-ampC isolates were from the blaDHA-1 subtype and carried ampR, a known transcriptional regulator of inducible beta-lactamase expression. Notably, five non-ampC carrying Klebsiella isolates displayed truncations in ompK35 and ompK36, which could potentially contribute to reduced cefoxitin susceptibility via porin loss. Conclusions: These findings underscore the limited diagnostic utility of cefoxitin susceptibility testing for detecting plasmid-mediated ampC producers and highlight the clinical relevance of regulatory genes such as ampR in mediating inducible resistance. The routine incorporation of molecular diagnostics or genome sequencing may be necessary to improve detection accuracy and inform antimicrobial stewardship strategies.
- 18 July 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (7) , 722
Open AccessShould Cefoxitin Non-Susceptibility in Ceftriaxone-Susceptible E. coli and K. pneumoniae Prompt Concerns Regarding Plasmid-Mediated AmpC Resistance? A Genomic Characterization and Summary of Treatment Challenges in Singapore
Objectives: Plasmid-mediated AmpC beta-lactamases represent a growing clinical concern in Enterobacterales, with challenges in diagnostic approaches, limited data on clinical outcomes, and our incomplete understanding of their regulatory mechanisms warranting the need for further investigation. Methods: This retrospective study examined the genomic and clinical characteristics of cefoxitin-non-susceptible, ceftriaxone-susceptible Escherichia coli and Klebsiella pneumoniae bloodstream isolates collected from a tertiary hospital in Singapore. Whole-genome sequencing was performed to detect ampC genes, subtypes, and associated regulatory elements. Results: Among 108 cefoxitin-non-susceptible isolates, only 15 (13.9%) harboured plasmid-mediated ampC, suggesting that cefoxitin non-susceptibility alone in ceftriaxone susceptible isolates was not predictive of ampC carriage. All plasmid-ampC isolates were from the blaDHA-1 subtype and carried ampR, a known transcriptional regulator of inducible beta-lactamase expression. Notably, five non-ampC carrying Klebsiella isolates displayed truncations in ompK35 and ompK36, which could potentially contribute to reduced cefoxitin susceptibility via porin loss. Conclusions: These findings underscore the limited diagnostic utility of cefoxitin susceptibility testing for detecting plasmid-mediated ampC producers and highlight the clinical relevance of regulatory genes such as ampR in mediating inducible resistance. The routine incorporation of molecular diagnostics or genome sequencing may be necessary to improve detection accuracy and inform antimicrobial stewardship strategies.
- 14 April 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1041-1048
Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19
We aimed to address factors contributing to the pharmacokinetic changes of nirmatrelvir/ritonavir in renal impaired (RI) patients and recommend dosing adjustment via a physiologically‐based pharmacokinetic (PBPK) modelling approach. A PBPK model of nirmatrelvir/ritonavir was developed via Simcyp® Simulator. Sensitivity analysis of the influence of hepatic CYP3A4 intrinsic clearance and abundance, as well as hepatic non‐CYP3A4 metabolism (other human liver microsomes [HLM] CLint) was performed to evaluate the effects of RI on oral clearance of nirmatrelvir. Other HLM CLint, the most sensitive parameter, was adjusted, and the simulated plasma concentration profiles of nirmatrelvir in severe RI subjects were within the therapeutic index of 292–10 000 ng/mL for dosing regimens of loading doses of 300/100 mg followed by 150/100 mg or 75/100 mg twice daily of nirmatrelvir/ritonavir. Considering that nirmatrelvir is available as a 150 mg tablet, we recommend 300/100 mg followed by 150/100 mg twice daily as the dosing regimen to be investigated in severe RI.
- 14 April 2024
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 91 (4) , 1041-1048
Physiologically‐based pharmacokinetic modelling guided dose evaluations of nirmatrelvir/ritonavir in renal impairment for the management of COVID‐19
We aimed to address factors contributing to the pharmacokinetic changes of nirmatrelvir/ritonavir in renal impaired (RI) patients and recommend dosing adjustment via a physiologically‐based pharmacokinetic (PBPK) modelling approach. A PBPK model of nirmatrelvir/ritonavir was developed via Simcyp® Simulator. Sensitivity analysis of the influence of hepatic CYP3A4 intrinsic clearance and abundance, as well as hepatic non‐CYP3A4 metabolism (other human liver microsomes [HLM] CLint) was performed to evaluate the effects of RI on oral clearance of nirmatrelvir. Other HLM CLint, the most sensitive parameter, was adjusted, and the simulated plasma concentration profiles of nirmatrelvir in severe RI subjects were within the therapeutic index of 292–10 000 ng/mL for dosing regimens of loading doses of 300/100 mg followed by 150/100 mg or 75/100 mg twice daily of nirmatrelvir/ritonavir. Considering that nirmatrelvir is available as a 150 mg tablet, we recommend 300/100 mg followed by 150/100 mg twice daily as the dosing regimen to be investigated in severe RI.
- Open Access
- 23 August 2023
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 12 (1) , 1-13
Antibiotic utilisation and resistance over the first decade of nationally funded antimicrobial stewardship programmes in Singapore acute-care hospitals
Objective: The aim of this study was to describe the time series of broad-spectrum antibiotic utilisation and incidence of antibiotic-resistant organisms during the implementation of antimicrobial stewardship programmes (ASP) in Singapore. Methods: An observational study was conducted using data from 2011 to 2020 in seven acute-care public hospitals. We applied joinpoint regressions to investigate changes in antibiotic utilisation rate and incidence density of antibiotic-resistant organisms. Results: Across the seven hospitals, quarterly broad-spectrum antibiotic utilisation rate remained stable. Half-yearly incidence density of antibiotic-resistant organisms with two joinpoints at first half (H1) of 2012 and second half (H2) of 2014 decreased significantly in the second and third period with a half-yearly percentage change (HPC) of -2.9% and − 0.5%, respectively. Across the five hospitals with complete data, half-yearly broad-spectrum antibiotic utilisation rate with one joinpoint decreased significantly from H1 of 2011 to H2 of 2018 (HPC − 4.0%) and H2 of 2018 to H2 2020 (HPC − 0.5%). Incidence density of antibiotic-resistant organisms decreased significantly in the two joinpoint periods from H1 of 2012 to H2 of 2014 (HPC − 2.7%) and H2 of 2014 to H2 of 2020 (HPC − 1.0%). Ceftriaxone with one joinpoint decreased significantly from H1 of 2011 to H1 of 2014 (HPC − 6.0%) and H1 of 2014 to H2 of 2020 (HPC − 1.8%) and ceftriaxone-resistant E. coli and K. pneumoniae decreased significantly in later periods, from H2 of 2016 to H2 of 2020 (HPC − 2.5%) and H1 of 2012 to H2 of 2015 (HPC − 4.6%) respectively. Anti-pseudomonal antibiotics with one joinpoint decreased significantly from H1 of 2011 to H2 of 2014 (HPC − 4.5%) and H2 of 2014 to H2 of 2020 (HPC − 0.8%) and that of quinolones with one joinpoint at H1 of 2015 decreased significantly in the first period. C. difficile with one joinpoint increased significantly from H1 of 2011 to H1 of 2015 (HPC 3.9%) and decreased significantly from H1 of 2015 to H2 of 2020 (HPC − 4.9%). Conclusions: In the five hospitals with complete data, decrease in broad-spectrum antibiotic utilisation rate was followed by decrease in incidence density of antibiotic-resistant organisms. ASP should continue to be nationally funded as a key measure to combat antimicrobial resistance in acute care hospitals.
- 23 August 2023
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 12 (1) , 1-13
Open AccessAntibiotic utilisation and resistance over the first decade of nationally funded antimicrobial stewardship programmes in Singapore acute-care hospitals
Objective: The aim of this study was to describe the time series of broad-spectrum antibiotic utilisation and incidence of antibiotic-resistant organisms during the implementation of antimicrobial stewardship programmes (ASP) in Singapore. Methods: An observational study was conducted using data from 2011 to 2020 in seven acute-care public hospitals. We applied joinpoint regressions to investigate changes in antibiotic utilisation rate and incidence density of antibiotic-resistant organisms. Results: Across the seven hospitals, quarterly broad-spectrum antibiotic utilisation rate remained stable. Half-yearly incidence density of antibiotic-resistant organisms with two joinpoints at first half (H1) of 2012 and second half (H2) of 2014 decreased significantly in the second and third period with a half-yearly percentage change (HPC) of -2.9% and − 0.5%, respectively. Across the five hospitals with complete data, half-yearly broad-spectrum antibiotic utilisation rate with one joinpoint decreased significantly from H1 of 2011 to H2 of 2018 (HPC − 4.0%) and H2 of 2018 to H2 2020 (HPC − 0.5%). Incidence density of antibiotic-resistant organisms decreased significantly in the two joinpoint periods from H1 of 2012 to H2 of 2014 (HPC − 2.7%) and H2 of 2014 to H2 of 2020 (HPC − 1.0%). Ceftriaxone with one joinpoint decreased significantly from H1 of 2011 to H1 of 2014 (HPC − 6.0%) and H1 of 2014 to H2 of 2020 (HPC − 1.8%) and ceftriaxone-resistant E. coli and K. pneumoniae decreased significantly in later periods, from H2 of 2016 to H2 of 2020 (HPC − 2.5%) and H1 of 2012 to H2 of 2015 (HPC − 4.6%) respectively. Anti-pseudomonal antibiotics with one joinpoint decreased significantly from H1 of 2011 to H2 of 2014 (HPC − 4.5%) and H2 of 2014 to H2 of 2020 (HPC − 0.8%) and that of quinolones with one joinpoint at H1 of 2015 decreased significantly in the first period. C. difficile with one joinpoint increased significantly from H1 of 2011 to H1 of 2015 (HPC 3.9%) and decreased significantly from H1 of 2015 to H2 of 2020 (HPC − 4.9%). Conclusions: In the five hospitals with complete data, decrease in broad-spectrum antibiotic utilisation rate was followed by decrease in incidence density of antibiotic-resistant organisms. ASP should continue to be nationally funded as a key measure to combat antimicrobial resistance in acute care hospitals.
- Open Access
- 21 July 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1521
Preferences of Healthcare Professionals on 3D-Printed Tablets: A Pilot Study
An inaugural study was performed to understand the perceptions of healthcare professionals toward the potential benefits of 3D printing in Singapore. This study sought to increase awareness of 3D printing applications for viable clinical applications and to elucidate the current gaps in therapy where 3D printing could play a role. A common example would be the use of 3D printing to manufacture polypills, thereby reducing the daily pill burden of patients and possibly improving medication adherence. A qualitative descriptive survey with a single-centered cross-sectional design was performed at Tan Tock Seng Hospital, a tertiary referral hospital with 1700 beds. This study had a total of 55 respondents comprising doctors and pharmacists. Most of the respondents viewed the 3D printing of oral dosage forms favorably and agreed about the potential advantages this technology could offer. More than 60% of the respondents were also willing to prescribe 3D printed tablets to patients. Respondents’ concerns were grouped into three main categories: formulation considerations, manufacturing processes, and administrative issues. Viewed in its entirety, this study provides a valuable starting point for understanding the perceptions of healthcare professionals in adopting 3D printing technology.
- 21 July 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (7) , 1521
Open AccessPreferences of Healthcare Professionals on 3D-Printed Tablets: A Pilot Study
An inaugural study was performed to understand the perceptions of healthcare professionals toward the potential benefits of 3D printing in Singapore. This study sought to increase awareness of 3D printing applications for viable clinical applications and to elucidate the current gaps in therapy where 3D printing could play a role. A common example would be the use of 3D printing to manufacture polypills, thereby reducing the daily pill burden of patients and possibly improving medication adherence. A qualitative descriptive survey with a single-centered cross-sectional design was performed at Tan Tock Seng Hospital, a tertiary referral hospital with 1700 beds. This study had a total of 55 respondents comprising doctors and pharmacists. Most of the respondents viewed the 3D printing of oral dosage forms favorably and agreed about the potential advantages this technology could offer. More than 60% of the respondents were also willing to prescribe 3D printed tablets to patients. Respondents’ concerns were grouped into three main categories: formulation considerations, manufacturing processes, and administrative issues. Viewed in its entirety, this study provides a valuable starting point for understanding the perceptions of healthcare professionals in adopting 3D printing technology.
- Open Access
- 3 May 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (5) , e2210180
Sustaining Antimicrobial Stewardship in a High–Antibiotic Resistance Setting
Antimicrobial stewardship has become an important strategy to tackle antimicrobial resistance. In 2017, the World Health Organization (WHO) categorized antibiotics into Access, Watch, and Reserve categories. Seven classes of antimicrobials, fluoroquinolones, third-generation cephalosporins, glycopeptides, antipseudomonal penicillins with β-lactamase inhibitors, and carbapenems, were on the Watch list.1 These are commonly used in hospitals and thus have been targeted by antimicrobial stewardship teams for interventions.2-5
- 3 May 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (5) , e2210180
Open AccessSustaining Antimicrobial Stewardship in a High–Antibiotic Resistance Setting
Antimicrobial stewardship has become an important strategy to tackle antimicrobial resistance. In 2017, the World Health Organization (WHO) categorized antibiotics into Access, Watch, and Reserve categories. Seven classes of antimicrobials, fluoroquinolones, third-generation cephalosporins, glycopeptides, antipseudomonal penicillins with β-lactamase inhibitors, and carbapenems, were on the Watch list.1 These are commonly used in hospitals and thus have been targeted by antimicrobial stewardship teams for interventions.2-5
- Open Access
- 31 January 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (2) , 184
Antibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When?
Background: COVID-19 imposes challenges in antibiotic decision-making due to similarities between bacterial pneumonia and moderate to severe COVID-19. We evaluated the effects of antibiotic therapy on the clinical outcomes of COVID-19 pneumonia patients and diagnostic accuracy of key inflammatory markers to inform antibiotic decision-making. Methods: An observational cohort study was conducted in patients hospitalised with COVID-19 at the National Centre for Infectious Diseases and Tan Tock Seng Hospital, Singapore, from January to April 2020. Patients were defined as receiving empiric antibiotic treatment for COVID-19 if started within 3 days of diagnosis. Results: Of 717 patients included, 86 (12.0%) were treated with antibiotics and 26 (3.6%) had documented bacterial infections. Among 278 patients with COVID-19 pneumonia, those treated with antibiotics had more diarrhoea (26, 34.7% vs. 24, 11.8%, p < 0.01), while subsequent admissions to the intensive care unit were not lower (6, 8.0% vs. 10, 4.9% p = 0.384). Antibiotic treatment was not independently associated with lower 30-day (adjusted odds ratio, aOR 19.528, 95% confidence interval, CI 1.039–367.021) or in-hospital mortality (aOR 3.870, 95% CI 0.433–34.625) rates after adjusting for age, co-morbidities and severity of COVID-19 illness. Compared to white cell count and procalcitonin level, the C-reactive protein level had the best diagnostic accuracy for documented bacterial infections (area under the curve, AUC of 0.822). However, the sensitivity and specificity were less than 90%. Conclusion: Empiric antibiotic use in those presenting with COVID-19 pneumonia did not prevent deterioration or mortality. More studies are needed to evaluate strategies to diagnose bacterial co-infections in these patients.
- 31 January 2022
- Published by MDPI AG in Antibiotics
- Vol. 11 (2) , 184
Open AccessAntibiotic Therapy in the Treatment of COVID-19 Pneumonia: Who and When?
Background: COVID-19 imposes challenges in antibiotic decision-making due to similarities between bacterial pneumonia and moderate to severe COVID-19. We evaluated the effects of antibiotic therapy on the clinical outcomes of COVID-19 pneumonia patients and diagnostic accuracy of key inflammatory markers to inform antibiotic decision-making. Methods: An observational cohort study was conducted in patients hospitalised with COVID-19 at the National Centre for Infectious Diseases and Tan Tock Seng Hospital, Singapore, from January to April 2020. Patients were defined as receiving empiric antibiotic treatment for COVID-19 if started within 3 days of diagnosis. Results: Of 717 patients included, 86 (12.0%) were treated with antibiotics and 26 (3.6%) had documented bacterial infections. Among 278 patients with COVID-19 pneumonia, those treated with antibiotics had more diarrhoea (26, 34.7% vs. 24, 11.8%, p < 0.01), while subsequent admissions to the intensive care unit were not lower (6, 8.0% vs. 10, 4.9% p = 0.384). Antibiotic treatment was not independently associated with lower 30-day (adjusted odds ratio, aOR 19.528, 95% confidence interval, CI 1.039–367.021) or in-hospital mortality (aOR 3.870, 95% CI 0.433–34.625) rates after adjusting for age, co-morbidities and severity of COVID-19 illness. Compared to white cell count and procalcitonin level, the C-reactive protein level had the best diagnostic accuracy for documented bacterial infections (area under the curve, AUC of 0.822). However, the sensitivity and specificity were less than 90%. Conclusion: Empiric antibiotic use in those presenting with COVID-19 pneumonia did not prevent deterioration or mortality. More studies are needed to evaluate strategies to diagnose bacterial co-infections in these patients.
- Open Access
- 24 November 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (12) , 1441
Hospital Pharmacists and Antimicrobial Stewardship: A Qualitative Analysis
Antimicrobial stewardship programmes (ASPs) in hospitals are predominantly led by specific ASP physicians and pharmacists. Limited studies have been conducted to appreciate non-ASP-trained hospital pharmacists’ perspectives on their roles in antimicrobial stewardship. Focus group discussions (FGDs) were conducted with 74 pharmacists, purposively sampled from the 3 largest acute-care public hospitals in Singapore, to explore facilitators and barriers faced by them in antimicrobial stewardship. Applied thematic analysis was conducted and codes were categorised using the social–ecological model (SEM). At the intrapersonal level, pharmacists identified themselves as reviewers for drug safety before dispensing, confining to a restricted advisory role due to lack of clinical knowledge, experience, and empowerment to contribute actively to physicians’ prescribing decisions. At the interpersonal level, pharmacists expressed difficulties conveying their opinions and recommendations on antibiotic therapy to physicians despite frequent communications, but they assumed critical roles as educators for patients and their caregivers on proper antibiotic use. At the organisational level, in-house antibiotic guidelines supported pharmacists’ antibiotic interventions and recommendations. At the community level, pharmacists were motivated to improve low public awareness and knowledge on antibiotic use and antimicrobial resistance. These findings provide important insights into the gaps to be addressed in order to harness the untapped potential of hospital pharmacists and fully engage them in antimicrobial stewardship.
- 24 November 2021
- Published by MDPI AG in Antibiotics
- Vol. 10 (12) , 1441
Open AccessHospital Pharmacists and Antimicrobial Stewardship: A Qualitative Analysis
Antimicrobial stewardship programmes (ASPs) in hospitals are predominantly led by specific ASP physicians and pharmacists. Limited studies have been conducted to appreciate non-ASP-trained hospital pharmacists’ perspectives on their roles in antimicrobial stewardship. Focus group discussions (FGDs) were conducted with 74 pharmacists, purposively sampled from the 3 largest acute-care public hospitals in Singapore, to explore facilitators and barriers faced by them in antimicrobial stewardship. Applied thematic analysis was conducted and codes were categorised using the social–ecological model (SEM). At the intrapersonal level, pharmacists identified themselves as reviewers for drug safety before dispensing, confining to a restricted advisory role due to lack of clinical knowledge, experience, and empowerment to contribute actively to physicians’ prescribing decisions. At the interpersonal level, pharmacists expressed difficulties conveying their opinions and recommendations on antibiotic therapy to physicians despite frequent communications, but they assumed critical roles as educators for patients and their caregivers on proper antibiotic use. At the organisational level, in-house antibiotic guidelines supported pharmacists’ antibiotic interventions and recommendations. At the community level, pharmacists were motivated to improve low public awareness and knowledge on antibiotic use and antimicrobial resistance. These findings provide important insights into the gaps to be addressed in order to harness the untapped potential of hospital pharmacists and fully engage them in antimicrobial stewardship.
- Open Access
- 1 March 2021
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 24, 45-47
A point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19)
- 1 March 2021
- Published by Elsevier in Journal of Global Antimicrobial Resistance
- Vol. 24, 45-47
Open AccessA point prevalence survey to assess antibiotic prescribing in patients hospitalized with confirmed and suspected coronavirus disease 2019 (COVID-19)
- Open Access
- 3 February 2021
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 10 (1) , 1-8
Effects of coronavirus disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore
Background: The deployment of antimicrobial stewardship (AMS) teams to deal with the COVID-19 pandemic can lead to a loss of developed frameworks, best practices and leadership resulting in adverse impact on antimicrobial prescribing and resistance. We aim to investigate effects of reduction in AMS resources during the COVID-19 pandemic on antimicrobial prescribing. Methods: One of 5 full-time equivalent AMS pharmacists was deployed to support pandemic work and AMS rounds with infectious disease physicians were reduced from 5 to 2 times a week. A survey in acute inpatients was conducted using the Global Point Prevalence Survey methodology in July 2020 and compared with those in 2015 and 2017–2019. Results: The prevalence of antimicrobial prescribing (55% in 2015 to 49% in 2019 and 47% in 2020, p = 0.02) and antibacterials (54% in 2015 to 45% in 2019 and 42% in 2020, p < 0.01) have been reducing despite the pandemic. Antimicrobial prescribing in infectious disease wards with suspected or confirmed COVID-19 cases was 29% in 2020. Overall, antimicrobial prescribing quality indicators continued to improve (e.g. reasons in notes, 91% in 2015 to 94% in 2019 and 97% in 2020, p < 0.01) or remained stable (compliance to guideline, 71% in 2015 to 62% in 2019 and 73% in 2020, p = 0.08). Conclusion: During the COVID-19 pandemic, there was no increase in antimicrobial prescribing and no significant differences in antimicrobial prescribing quality indicators.
- 3 February 2021
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 10 (1) , 1-8
Open AccessEffects of coronavirus disease 2019 (COVID-19) pandemic on antimicrobial prevalence and prescribing in a tertiary hospital in Singapore
Background: The deployment of antimicrobial stewardship (AMS) teams to deal with the COVID-19 pandemic can lead to a loss of developed frameworks, best practices and leadership resulting in adverse impact on antimicrobial prescribing and resistance. We aim to investigate effects of reduction in AMS resources during the COVID-19 pandemic on antimicrobial prescribing. Methods: One of 5 full-time equivalent AMS pharmacists was deployed to support pandemic work and AMS rounds with infectious disease physicians were reduced from 5 to 2 times a week. A survey in acute inpatients was conducted using the Global Point Prevalence Survey methodology in July 2020 and compared with those in 2015 and 2017–2019. Results: The prevalence of antimicrobial prescribing (55% in 2015 to 49% in 2019 and 47% in 2020, p = 0.02) and antibacterials (54% in 2015 to 45% in 2019 and 42% in 2020, p < 0.01) have been reducing despite the pandemic. Antimicrobial prescribing in infectious disease wards with suspected or confirmed COVID-19 cases was 29% in 2020. Overall, antimicrobial prescribing quality indicators continued to improve (e.g. reasons in notes, 91% in 2015 to 94% in 2019 and 97% in 2020, p < 0.01) or remained stable (compliance to guideline, 71% in 2015 to 62% in 2019 and 73% in 2020, p = 0.08). Conclusion: During the COVID-19 pandemic, there was no increase in antimicrobial prescribing and no significant differences in antimicrobial prescribing quality indicators.